Señalización PI3K / Akt / mTOR
Los inhibidores de la señalización PI3K/Akt/mTOR son compuestos que se dirigen a las vías de la fosfoinositida 3-cinasa (PI3K), la cinasa Akt y el blanco de la rapamicina en mamíferos (mTOR). Estas vías son reguladores críticos del crecimiento celular, la supervivencia, el metabolismo y la autofagia, lo que las convierte en objetivos clave en la investigación del cáncer y los trastornos metabólicos. Inhibir estas vías puede ayudar a controlar el crecimiento y la proliferación tumoral, ofreciendo potenciales estrategias terapéuticas para varios tipos de cáncer y otras enfermedades caracterizadas por una señalización celular desregulada. En CymitQuimica, ofrecemos una amplia selección de inhibidores de alta calidad de PI3K/Akt/mTOR para apoyar su investigación en oncología, señalización celular y enfermedades metabólicas.
Subcategorías de "Señalización PI3K / Akt / mTOR"
- AMPK(158 productos)
- ATM / ATR(71 productos)
- ADN-PK(51 productos)
- EGFR(572 productos)
- MELK(7 productos)
- PDK(9 productos)
- PI3K(242 productos)
- Quinasa S6(9 productos)
- gsk-3(112 productos)
- mTOR(144 productos)
Mostrar 2 subcategorías más
Se han encontrado 1038 productos de "Señalización PI3K / Akt / mTOR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
DSPE-PEG5000-GE11
<p>DSPE-PEG5000-GE11 is a PEG compound composed of DSPE and the EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells with EGFR overexpression. DSPE-PEG5000-GE11 is utilized in drug delivery.</p>Forma y color:Odour SolidMS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Fórmula:C48H58ClFN8O12Forma y color:SolidPeso molecular:993.47EGFR T790M/L858R-IN-9
<p>EGFRT790M/L858R-IN-9 (Compound 8) is an inhibitor targeting the EGFR-L858R/T790M mutations. It effectively inhibits the phosphorylation of the EGFR-L858R/T790M mutant kinase, demonstrating an IC50 value of 0.0064 µM. Additionally, EGFRT790M/L858R-IN-9 can suppress the proliferation of non-small cell lung cancer (NSCLC) cells, making it useful for cancer research.</p>Fórmula:C26H27N7O3SForma y color:SolidPeso molecular:517.603HL-8
CAS:<p>HL-8, a PROTAC targeting PI3K, degrades it fully at 10 μM in 8h, useful in cancer research.</p>Fórmula:C57H59F2N11O9S2Forma y color:SolidPeso molecular:1144.27GSK3β/mTOR modulator 1
<p>GSK3β/mTOR modulator 1 (derivative 2) is an agent that modulates the GSK3β/mTOR signaling pathway. It is applicable in research related to acute lung injury (ALI) and inflammation.</p>Fórmula:C19H28O5Forma y color:SolidPeso molecular:336.19367Anti-ERBB3/HER3 (29Z6)
<p>Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor targeting human ERBB3/HER3.</p>Forma y color:Odour LiquidEGFR-IN-22
CAS:<p>EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).</p>Fórmula:C38H47BrFN10O2PForma y color:SolidPeso molecular:805.72JBJ-09-063 TFA
<p>JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.</p>Fórmula:C33H30F4N4O5SForma y color:SolidPeso molecular:670.67Varlitinib
CAS:<p>Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.</p>Fórmula:C22H19ClN6O2SPureza:99.7%Forma y color:SolidPeso molecular:466.94EGFR/VEGFR2-IN-5
<p>EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.</p>Fórmula:C17H15N7O5SForma y color:SolidPeso molecular:429.41DS06652923
<p>DS06652923 is an orally active inhibitor targeting EGFR triple mutations. It exhibits growth-inhibitory effects on Ba/F3EGFRdel19/T90M/C795S cells, with a GI50 value of 9.4 nM. Additionally, DS06652923 induces tumor regression in the Ba/F3 syngeneic transplantation model.</p>Forma y color:Odour SolidDA-143
<p>DA-143 is a selective inhibitor of DNA-PKcs (IC50: 2.5 nM), demonstrating disparate inhibitory effects on mTOR, PI3KΔ, and ATM, with IC50 values of 280 nM, 106 nM, and 6,594 nM, respectively. This compound effectively blocks the phosphorylation of DNA-PKcs substrates and enhances the sensitivity of cancer cells to doxorubicin.</p>Forma y color:Odour SolidPROTAC EGFR degrader 2
<p>Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.</p>Fórmula:C58H72ClFN12O8SForma y color:SolidPeso molecular:1151.78ALKBH1-IN-3
<p>ALKBH1-IN-3 is an effective inhibitor of the DNA N6-methyladenosine (6mA) demethylase ALKBH1. This compound enhances the abundance of 6mA in gastric cancer cell lines HGC27 and AGS, simultaneously inhibiting cell viability and upregulating the AMP-activated protein kinase (AMPK) signaling pathway. ALKBH1-IN-3 holds potential for use in cancer research, including studies on gastric cancer.</p>Forma y color:Odour SolidARRY-380 (analog )
CAS:<p>ARRY-380 analog (HER2-Inhibitor-1) is a potent and selective HER2 inhibitor.</p>Fórmula:C29H27N7O4SPureza:99.82%Forma y color:SolidPeso molecular:569.63FAP-PI3KI1
CAS:<p>FAP-PI3KI1: A FAP-targeted PI3K inhibitor reducing collagen synthesis in human IPF cells.</p>Fórmula:C52H48F4N10O12S3Forma y color:SolidPeso molecular:1177.19EGFR-IN-124
<p>EGFR-IN-124 (compound 10A) is an EGFR inhibitor with an IC50 value of 0.54 μM, utilized in cancer research.</p>Forma y color:Odour SolidEGFR-IN-127
<p>EGFR-IN-127 is an ATP-competitive inhibitor targeting EGFR, with IC50 values of 136.3 nM for EGFRdel19 and 161.2 nM for EGFRdel19/T790M/C797S. This compound holds potential for the study of non-small cell lung cancer (NSCLC).</p>Forma y color:Odour SolidIC 86621
CAS:<p>IC 86621: DNA-PK ATP-competitive inhibitor, IC50 120 nM, enhances DSB antitumor effects, EC50 68 µM for repair.</p>Fórmula:C12H15NO3Pureza:99.68%Forma y color:SolidPeso molecular:221.25GSK-3β inhibitor 21
<p>GSK-3β Inhibitor21 (compound 44) is an ATP-competitive inhibitor of GSK-3β with an IC50 value of 6.06 µM, characterized by its ability to inhibit tau phosphorylation and prevent amyloid protein aggregation. This compound is utilized in the research of Alzheimer's disease.</p>Forma y color:Odour SolidCetuximab MMAE
<p>Cetuximab-MMAE, an antibody-drug conjugate (ADC), combines an EGFR-targeting antibody with Monomethyl auristatin E (MMAE) to investigate colorectal and head and neck cancers.</p>Forma y color:LiquidPeso molecular:150 kDaUmbralisib R-enantiomer
CAS:<p>Umbralisib R-enantiomer (RP5264 R-enantiomer) is a delta inhibitor of PI3K and a less active enantiomer of TGR-1202.</p>Fórmula:C31H24F3N5O3Pureza:97.34%Forma y color:SolidPeso molecular:571.55GSK-3β inhibitor 24
<p>GSK-3β inhibitor24 (Compound 41) is a potent GSK-3β inhibitor with an IC50 of 0.22 nM. It increases GSK-3β phosphorylation at the Ser9 site in a dose-dependent manner and inhibits tau protein hyperphosphorylation by reducing the abundance of p-tau-Ser396. The compound upregulates β-catenin and neurogenesis-related markers (GAP43 and MAP-2), demonstrating significant anti-Alzheimer's disease (AD) activity.</p>Fórmula:C26H18N4O3Forma y color:SolidPeso molecular:434.446HER2/neu (654-662) GP2
CAS:<p>Phage display selected Affibody ligands for HER2/neu from a protein library based on a 58-residue Staphylococcal protein A Z domain.</p>Fórmula:C42H77N9O11Pureza:98%Forma y color:SolidPeso molecular:884.11EGFR/PI3Kα-IN-1
<p>EGFR/PI3Kα-IN-1 (compound 30k), a dual EGFR/PI3Kα inhibitor, exhibits potent activity with IC 50 values of 3.6 nM (EGFRL858R/T790M) and 30 nM (PI3Kα). It effectively inhibits tumor cell proliferation and demonstrates significant anticancer activity.</p>Fórmula:C50H49N11O5SForma y color:SolidPeso molecular:916.06GSK-3β inhibitor 23
<p>GSK-3β inhibitor23 (Compound 11726169) is an inhibitor of glycogen synthase kinase 3 (GSK-3), effectively inhibiting GSK-3β and GSK-3α with IC50 values of 12.1 nM and 18.8 nM, respectively. It demonstrates antiviral activity against HIV1 and exhibits good metabolic stability in mouse and human liver microsomes and plasma, although it has poor permeability in Caco-2 cells, indicating potentially low oral bioavailability.</p>Fórmula:C18H13Cl2N5O2SForma y color:SolidPeso molecular:434.299Tephrosin
CAS:<p>Tephrosin induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors, has potent antitumor activities.</p>Fórmula:C23H22O7Pureza:98%Forma y color:SolidPeso molecular:410.42MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate
CAS:<p>MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate is a conjugate formed by linking MC-Val-Cit-PAB-Amide and TLR7 agonist 4, useful for cancer research.</p>Fórmula:C52H72N12O11Pureza:97.70%Forma y color:SolidPeso molecular:1041.2IBI-334
<p>IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.</p>Forma y color:Odour LiquidGSK-3β inhibitor 19
<p>GSK-3β Inhibitor 19 (compound 36) is an inhibitor of GSK-3β with an IC50 value of 70 nM. It is applicable in research related to anti-inflammatory and Alzheimer's disease.</p>Fórmula:C15H12N4O2SForma y color:SolidPeso molecular:312.35YH32367
<p>YH32367 (ABL105) is a bispecific antibody targeting HER2 and 4-1BB. It induces the secretion of IFN-γ, resulting in the death of tumor cells when co-cultured with hPBMC and HER2-expressing tumor cells. YH32367 demonstrates notable antitumor activity.</p>Forma y color:Odour LiquidTimigutuzumab
CAS:<p>Timigutuzumab (GEXMab73) is a humanized monoclonal antibody designed to target ErbB2, showing potential application in cancer research [1].</p>Forma y color:LiquidAnticancer agent 271
<p>Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.</p>Forma y color:Odour SolidWAY-270360
CAS:<p>WAY-270360 (N-[4-(1H-benzimidazol-2-yl)phenyl]-2,4-dimethoxybenzamide) is a sirtuin modulator and an epidermal growth factor receptor (EGFR) inhibitor.</p>Fórmula:C22H19N3O3Pureza:98.05%Forma y color:SolidPeso molecular:373.4DSPE-PEG1000-GE11
<p>DSPE-PEG1000-GE11 is a PEG compound made up of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells overexpressing EGFR. DSPE-PEG1000-GE11 serves a role in drug delivery.</p>Forma y color:Odour SolidPX-866-17OH
CAS:<p>PX-866-17OH can be used in related research in the field of life sciences. Its product number is T36312 and CAS number is 1012327-63-7.</p>Fórmula:C29H37NO8Forma y color:SolidPeso molecular:527.61IHMT-PI3K-315
<p>IHMT-PI3K-315 (20e) serves as a potent, selective inhibitor of PI3Kγ/δ, exhibiting IC 50 values of 4.0 nM for PI3Kγ and 9.1 nM for PI3Kδ. Additionally, it demonstrates antitumor activity.</p>Fórmula:C22H20F2N6O4Forma y color:SolidPeso molecular:470.43Varlitinib Tosylate
CAS:<p>Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).</p>Fórmula:C36H35ClN6O8S3Pureza:98%Forma y color:SolidPeso molecular:811.34RMC-4529
CAS:<p>RMC-4529 is a chemical compound that demonstrates potent inhibition, with an IC50 value of 1.0 nM, against p-4E-BP1-(T37/46) in mTOR kinase cellular assays.</p>Fórmula:C90H139N13O23Forma y color:SolidPeso molecular:1771.17Lyso-Monosialoganglioside GM3
CAS:<p>Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.</p>Fórmula:C41H74N2O20Forma y color:SolidPeso molecular:915.028GSK2292767 FA
<p>GSK2292767 FA: potent PI3Kδ inhibitor, pIC50=10.1, 500x selectivity, for respiratory research.</p>Fórmula:C25H30N6O7SPureza:99.52%Forma y color:SoildPeso molecular:558.61AZ14240475
<p>AZ14240475 is a potent, selective, brain-penetrant inhibitor of EGFREx20Ins mutants (EGFREx20Ins mutants) with a pIC50 of 7.6, playing a significant role in cancer research.</p>Fórmula:C23H15ClF2N6O2Forma y color:SolidPeso molecular:480.854EGFR-IN-148
<p>EGFR-IN-148 (compound 8c) is a potent EGFR inhibitor with an IC50 of 0.161 μM. It induces G1/S phase arrest and significantly enhances apoptosis in HepG2 cells.</p>Fórmula:C17H16N4O4SForma y color:SolidPeso molecular:372.398Inetetamab
<p>Inetetamab is a recombinant humanized antibody targeting HER2 receptor domain IV, with anticancer activity, inducing pyroptosis in lung adenocarcinoma.</p>Pureza:96.54% (SEC-HPLC) - 96.54% (SEC-HPLC)Forma y color:Odour LiquidPI3K-IN-22
CAS:<p>PI3K-IN-22 is a dual kinase inhibitor of PI3Kα and mTOR, with IC50s of 0.9 and 0.6 nM respectively. PI3K-IN-22 could be used in cancer.</p>Fórmula:C31H35F3N8O3Forma y color:SolidPeso molecular:624.66GW 583340
CAS:<p>GW 583340 is a potent and selective dual inhibitor of EGFR/ErbB2 tyrosine kinase with the advantage of oral dosability and antitumor effects.</p>Fórmula:C28H25ClFN5O3S2Pureza:98.68%Forma y color:SoildPeso molecular:598.11PI3Kα-IN-25
<p>PI3Kα-IN-25 (Compound Djh1) is a selective inhibitor of PI3Kα, suitable for research in triple-negative breast cancer.</p>Fórmula:C21H19ClN4O4Forma y color:SolidPeso molecular:426.853mTOR inhibitor 9f
CAS:<p>mTOR inhibitor 9f is a selective mTOR inhibitor with IC50 of 1.25nM and 82nM for mTOR and PI3Kα, respectively.</p>Fórmula:C25H23N5O2SPureza:99.18%Forma y color:SoildPeso molecular:457.55CZY43
<p>CZY43 is an HER3 degrader that effectively induces degradation of HER3 in breast cancer SKBR3 cells in a dose- and time-dependent manner. It efficiently inhibits HER3-dependent signaling and cancer cell growth, outperforming Bosutinib.</p>Fórmula:C42H53Cl2N5O3Forma y color:SolidPeso molecular:746.808RMC-4627
CAS:<p>RMC-4627 is a selective mTORC1 inhibitor that activates 4EBP1 and inhibits tumor growth.</p>Fórmula:C93H141N11O23Forma y color:SolidPeso molecular:1781.17
